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MD, 5) Pﬁzer Inc., San Diego, CA, USA, 6) Pﬁzer Inc., Paris, France and 7) Pﬁzer Inc., Groton, CT, USAAbstractDiabetes mellitus affects 284 million adults worldwide and is increasing in prevalence. Accelerated atherosclerosis in patients with diabetes
mellitus contributes an increased risk of developing cardiovascular diseases including peripheral vascular disease (PVD). Immune dysfunction,
diabetic neuropathy and poor circulation in patients with diabetes mellitus, especially those with PVD, place these patients at high risk for
many types of typical and atypical infections. Complicated skin and soft-tissue infections (cSSTIs) are of particular concern because skin
breakdown in patients with advanced diabetes mellitus and PVD provides a portal of entry for bacteria. Patients with diabetes mellitus
are more likely to be hospitalized with cSSTIs and to experience related complications than patients without diabetes mellitus. Patients
with PVD requiring lower extremity bypass are also at high risk of surgical site and graft infections. Methicillin-resistant Staphylococcus
aureus (MRSA) is a frequent causative pathogen in cSSTIs, and may be a signiﬁcant contributor to surgical site infections, especially in
patients who are colonized with MRSA on hospital admission. Patients with cSSTIs and diabetes mellitus or PVD experience lower
clinical success rates than patients without these comorbidities, and may also have a longer length of hospital stay and higher risk of
adverse drug events. Clinicians should be vigilant in recognizing the potential for infection with multi-drug-resistant organisms, especially
MRSA, in these populations and initiating therapy with appropriate antibiotics.
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This is an open access artiEpidemiology and pathophysiology of
peripheral vascular disease and diabetes
mellitusIt is estimated that over 284 million adults were living with
diabetes mellitus worldwide in 2010, and this number is ex-
pected to increase by 54% by 2030 [1]. Comorbid peripheral
vascular disease (PVD) is present in 9.5% of patients 40 years
old with diabetes mellitus [2], and the risk of developing PVD is
up to four-fold higher in patients with diabetes mellitus
compared with patients without diabetes mellitus [3]. TheClin Microbiol Infect 2015; 21: S27–S32
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mellitus, with a relative risk of 1.39 for patients diagnosed with
diabetes mellitus 1–5 years ago, and 4.5 for patients diagnosed
more than 25 years ago [4].
The pathophysiology of atherosclerosis leading to PVD in
patients with diabetes mellitus is multifactorial [5,6]. In the
blood vessels, hyperglycaemia is thought to impair nitric oxide-
mediated vasodilatation and enhance the formation of advanced
glycation endproducts, leading to increases in pro-inﬂammatory
factors. Hyperglycaemia may also lead to atherosclerotic plaque
instability by enhancing the oxidation of glycated low-density
lipoprotein. Pro-coagulant effects may arise from elevated
levels of C-reactive protein and coagulation factors, in addition
to platelet hyper-reactivity. Taken together, these processes
result in accelerated atherogenesis and diabetic atheropathy,
leading to microvascular and macrovascular complications,
including PVD [5].Altered immune function in diabetes mellitus
and PVDPotential mechanisms for altered immune function in patients
with diabetes mellitus are shown in Table 1. Changes in leu-
cocyte function ﬁgure prominently and are believed to result
from hyperglycaemia, as they are ameliorated by adequate
glycaemic control [7]. It is believed that, in the presence of
elevated blood glucose, polymorphonuclear lymphocytes are
continually activated at baseline and so are less responsive to
infectious stimuli [8]. Increased resting levels of pro-
inﬂammatory cytokines contribute both to an insufﬁcient im-
mune response to pathogens and to vascular inﬂammation [8].
Both PVD and diabetic neuropathy may contribute to a
propensity for infection and poor outcomes among patients
with diabetes. Substance P and nerve growth factor promote
immune cell chemotaxis and proliferation, and decreased pro-
duction of these neuropeptides in patients with diabetic neu-
ropathy can slow wound healing [9]. In addition, leucocyteTABLE 1. Mechanisms of altered immune function in patients
with diabetes mellitus [7,8]
Humoral mechanisms Cellular mechanisms
Decreased levels of complement C4
Increased background levels of
tumour necrosis factor-α,
interleukin-6 and interleukin-8
with impaired response to stimulation
Impaired polymorphonuclear
cell and neutrophil chemotaxis
and phagocytosis
Impaired killing by
polymorphonuclear cells
Decreased lymphocyte
proliferative response to
pathogens including
Staphylococcus aureus
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Movement of immune cells and nutrients to the site of infection
may be further impaired in patients with PVD as the result of
prolonged inﬂammation resulting in thickening of capillary
basement membranes [9]. Comorbid renal impairment in pa-
tients with PVD and diabetes mellitus is associated with further
impairment in host defences [11].Infection risk and outcomesAltered immune function in patients with diabetes mellitus leads
to an increased risk of multiple types of infections. Atypical
infections that occur more frequently in patients with diabetes
mellitus include streptococcal and Fournier’s gangrene [12],
rhinocerebral mucormycosis [8] and malignant otitis externa
[8]. However, because these infections are relatively rare, the
burden of infection in patients with diabetes mellitus lies pri-
marily with more common infection types (Table 2).
A number of studies have evaluated infection risk among
patients with diabetes mellitus. Shah and Hux conducted a
retrospective cohort study matching over 500 000 patients in
Ontario with diabetes mellitus to non-diabetic controls using
administrative claims data [13]. Almost half of the patients with
diabetes had at least one hospitalization or physician claim for
an infectious disease during the study year (risk ratio
(RR) = 1.21; 95% CI 1.20–1.22 versus non-diabetic patients),
with 5% being hospitalized (RR = 2.01; 95% CI 1.96–2.06). Risk
of nearly every type of infection studied was higher among
patients with diabetes, with the highest risk ratios seen for
osteomyelitis (RR = 4.39; 95% CI 3.80–5.06), sepsis (RR = 2.45;
95% CI 2.23–2.68), post-operative infections (RR = 2.02, 95%
CI 1.80–2.27) and cellulitis (RR = 1.81; 95% CI 1.76–1.86).
Only herpes simplex virus infection, mastoiditis, human im-
munodeﬁciency virus infection and appendicitis did not occur
more frequently in patients with diabetes mellitus [13]. These
ﬁndings were conﬁrmed by Hamilton et al. in a prospective
cohort study in Australia, with risk of hospitalization for an
infection increased two-fold among patients with diabetes
mellitus (incident rate ratio = 2.13; 95% CI 1.88–2.42) [14]. In a
Danish population, Benﬁeld et al. found that patients withTABLE 2. Common infections with at least two-fold increased
risk in patients with diabetes mellitus [13–15]
Osteomyelitis
Sepsis
Post-operative infections
Skin and soft-tissue infections/cellulitis
Urinary tract infection
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diabetes mellitus to be hospitalized for an infection (hazard
ratio = 3.05; 95% CI 2.47–3.78) [15].
In addition to being at greater risk of developing various
infections, patients with diabetes mellitus are at high risk of
mortality when such infections occur. Regardless of study
design, population and type of infection, mortality is increased
approximately two-fold in patients with diabetic versus non-
diabetic patients [16–19]. Among patients with diabetes with
concomitant cardiovascular disease, infection-related mortality
was increased three-fold [16].
Skin and soft-tissue infections are of particular concern in
patients with diabetes mellitus, especially those with comorbid
PVD, because skin breakdown provides a route of entry for
bacteria. Suaya et al. conducted a retrospective cohort study
using a US healthcare claims database to estimate rates of SSTIs
and their complications among patients with and without dia-
betes mellitus [20]. Infections were identiﬁed using Interna-
tional Classiﬁcation of Diseases, 9th revision (ICD-9) codes and
classiﬁed as occurring in the ambulatory or inpatient setting,
depending on the place of service for the ICD-9 code. Infor-
mation on SSTI complications, including lymphadenitis,
myositis/necrotizing fasciitis, gangrene, osteomyelitis, bacter-
aemia, endocarditis, septicaemia and sepsis, was also collected.
During the study period (2005–2010), over 2 million SSTI
episodes occurred in patients with and without diabetes. The
distribution of infection sites for ambulatory infections was
signiﬁcantly different between the two populations (p < 0.01),
with patients with diabetes mellitus having more abscesses/
cellulitis (65.6% versus 59.3% of SSTIs in the diabetic and non-
diabetic groups, respectively), decubitus ulcers (8.1% versus
0.9%), and surgical site infections (3.6% versus 1.9%), but a
smaller proportion of folliculitis, impetigo, furuncles, mastitis
and other SSTIs (22.6% versus 37.8% for these infections
combined). For infections diagnosed in inpatient settings, de-
cubitus ulcers were more common among patients with dia-
betes (15.2% versus 3.2%) but the distribution of other
infection types was similar. Patients with diabetes mellitus were
more likely to have an SSTI-associated complication compared
with patients without diabetes mellitus (4.9% versus 0.85% for
ambulatory infections and 36.7% versus 21.7% for inpatient
settings; p < 0.01 for both), with the highest complication rates
for both groups among patients with decubitus ulcers (32.4%
versus 13.3% for ambulatory and 63.1% versus 51.4% for
inpatient settings) [20].
While foot infections are a major source of morbidity and
mortality among patients with diabetes mellitus, cellulitis and
infected ulcers at other sites contribute signiﬁcantly to infec-
tious burden in these patients [21]. In a retrospective cohort
study of 3030 hospitalized patients with diabetes mellitus and© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behal
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locations other than the foot, the majority of which were
cellulitis [21]. Patients with non-foot infections are more likely
to have congestive heart failure, chronic lung disease, chronic
renal failure, history of amputation, hospital admission in the
last 30 days, to be admitted from skilled nursing facility, and be
hypoglycaemic or have altered mental status on admission.
Outcomes were similar between foot and non-foot infections
after adjusting for comorbidities and other confounders.
Because advanced PVD may require surgical revasculariza-
tion, infections at surgical sites and vascular grafts are of
particular concern. Data from the National Surgical Quality
Improvement Program in the USA showed that surgical site
infections occurred in 11% of patients undergoing lower ex-
tremity bypass surgery between 2005 and 2007, and diabetes
mellitus was associated with a signiﬁcant increase in risk
(OR = 1.5; 95% CI 1.2–1.8) [22]. Patients who developed a
surgical site infection were at increased risk of graft failure
requiring intervention or revision (OR = 2.4; 95% CI 1.9–3.1),
sepsis (OR = 6.5; 95% CI 5.1–8.3) and septic shock (OR = 2.4;
95% CI 1.8–3.4). Risk of graft infection is also increased in
patients with diabetes mellitus (hazard ratio = 4.6; 95% CI
1.5–14.3 versus patients without diabetes mellitus), with only
71% of patients with a graft infection free of major amputation
at 1 year [23].Methicillin-resistant Staphylococcus aureus
SSTIsEpidemiology
Staphylococcus aureus is responsible for more SSTIs than any
other pathogen worldwide. Data from the SENTRY Antimi-
crobial Surveillance Program (1998–2004) indicated that
S. aureus accounted for approximately half all of cases in North
America and one-third of cases in Latin America and Europe in
2004 [24]. A prospective cohort of patients in four teaching
hospitals in China found that S. aureus was the infecting or-
ganism in nearly one-third of SSTIs in 2009–10 [25].
The percentage of S. aureus isolates resistant to methicillin
varies greatly among countries and within geographical regions.
The percentage of methicillin-resistant isolates in 2004 was
35.9%, 29.4%, and 22.5% in North America, Latin America and
Europe, respectively [24]. Recent data suggest that the
methicillin-resistant S. aureus (MRSA) rate in many European
countries is declining or at least stabilizing [26]. However,
methicillin resistance remains greater than 25% in 7 European
countries (Cyprus, Greece, Italy, Malta, Poland, Portugal,
Romania), and more than 50% in several geographical regionsf of European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, S27–S32
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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Europe were resistant to methicillin in 2009 and 17.8% in 2012
[26]. In 2011, the CHINET bacterial surveillance system esti-
mated the MRSA prevalence among S. aureus isolates in China
at 50.6% [32]. A recent meta-analysis of studies conducted in
Africa and the Middle East estimated that 42.1% of S. aureus
SSTI isolates were methicillin-resistant [33].
Historically, MRSA has been responsible for nosocomial in-
fections, but community-acquired (CA-) strains are emerging
worldwide [34]. Pooled CA-MRSA prevalence rates have been
estimated at 23.1%, 37.4% and 47.4% in Asia, Europe and North
America, respectively [35]. CA-MRSA generally affects younger
patients, members of the military, athletes and intravenous drug
users, whereas healthcare-acquired infections occur more
frequently in patients who are residents of long-term care fa-
cilities, those with prolonged hospitalizations, or who are
housed in intensive care units [36]. Although diabetes mellitus is
a well-recognized risk factor for hospital-acquired MRSA cSSTIs
[36], it has more recently been shown that patients with dia-
betes mellitus are twice as likely to present to a US emergency
department with a CA-MRSA cSSTI compared with patients
without diabetes mellitus [37]. Among patients with diabetes
mellitus who are hospitalized for SSTI, MRSA is more likely to
be isolated from non-foot infections than foot infections (9.6%
versus 7.4%; p < 0.01) [21].
Colonization with MRSA, predominantly in the nares, is a
well-recognized risk factor for hospital-acquired and surgical
site infections [38,39]. Diabetes mellitus is associated with an
increased likelihood of MRSA colonization upon hospital
admission [40] and PVD has been shown to increase risk of
developing colonization during a hospitalization [41] or nursing
home stay [42]. In addition, PVD is a risk factor for conversionFIG. 1. Methicillin-resistant Staphylococcus aureus prevalence by geographical
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Among patients undergoing vascular surgery (40% of whom
had diabetes mellitus), Taylor and Napolitano found that 35% of
post-operative infections were due to MRSA, with 61% of these
being surgical site infections [44]. Length of stay for patients
with a post-operative MRSA infection was nearly 7 days longer
than for patients without a hospital-acquired infection, and over
4 days longer than for patients with an infection caused by
another organism.
Outcomes
Inadequate tissue perfusion leading to poor antibiotic pene-
tration and underlying immune defects may contribute to poor
cSSTI outcomes for patients with diabetes mellitus and pe-
ripheral vascular disease. Few studies have quantiﬁed the impact
of these disorders on outcomes among patients with MRSA
cSSTIs.
Lipsky et al. conducted a pooled analysis of three randomized
trials to compare outcomes among diabetic and non-diabetic
patients with MRSA cSSTIs [21]. The studies comprised 349
patients with diabetes mellitus and 707 non-diabetic patients
who had received either vancomycin or linezolid. Patients with
diabetes mellitus were more likely to have infected skin ulcers
and less likely to have abscesses compared with non-diabetic
patients, and more likely to have comorbid vascular and renal
disease, but the groups were otherwise similar. Clinical success,
deﬁned as resolution of all clinical signs and symptoms of
infection identiﬁed at baseline, was achieved by fewer patients
with diabetes mellitus compared with those without diabetes
mellitus (72.3% versus 85.8%; adjusted OR = 0.4; 95% CI
0.3–0.6). Patients with diabetes mellitus also had a longer lengthregion (data collection year[s]) [26–31].
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tients; p < 0.0001).
In a similar analysis of data from two clinical trials, Duane
et al. evaluated the impact of vascular disease in patients with
lower extremity MRSA cSSTIs [45]. Of the 477 patients
included in the study, 274 were identiﬁed as having vascular
disease. These patients were signiﬁcantly older, weighed more,
and were more likely to have diabetes mellitus, renal impair-
ment, coronary artery disease and hyperlipidaemia than pa-
tients without vascular disease. In addition, patients with
vascular disease were more likely to have infected ulcers and
less likely to have abscesses than patients without vascular
disease. Unadjusted clinical success rates at the end of the study
were 73.5% and 91.8% for patients with and without vascular
disease, respectively; adjusted rates were not given. Patients
with vascular disease also had a higher frequency of adverse
drug events and serious adverse drug events compared with
patients without vascular disease.ConclusionsWorldwide, the prevalence of diabetes mellitus is increasing
exponentially. Patients with diabetes mellitus, and especially
those with comorbid PVD, are at increased risk of many types
of infections. Of these, SSTIs are of concern for two reasons.
First, immune defects in patients with diabetes mellitus lead to a
decreased response to the most common SSTI pathogen,
S. aureus. Second, skin breakdown leading to ulceration pro-
vides a route of entry for bacteria. As the population of patients
with diabetes mellitus grows, so does the burden of infection
for this population.
Approximately one-third of S. aureus isolates causing cSSTIs
are resistant to methicillin. Frequent hospitalizations and
surgeries among patients with diabetes mellitus and PVD in-
crease the risk of hospital-acquired MRSA, and diabetes mel-
litus is an emerging risk factor for CA-MRSA as well. It has
been shown that patients with diabetes mellitus or PVD and
MRSA cSSTIs have poorer clinical outcomes than patients
without these comorbidities, adding to the burden of in-
fections in these populations. As a result, clinicians should be
vigilant in recognizing these infections and initiating therapy
with appropriate antibiotics in order to assist in alleviating this
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